LLY
Eli Lilly and Company
LLY has the edge over QTRX overall, supported by stronger fundamentals and lower modeled downside.
QTRX
Quanterix Corporation
QTRX's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
QTRX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Unavailable |
QTRX's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
QTRX PE Valuation
QTRX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over QTRX on the outlook, with more favorable revenue expectations.
QTRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect QTRX's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over QTRX on earnings quality, reporting a profit while its opponent remains loss making.
QTRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.35 | -$0.02 |
| Q2 2026 | -$2.62 | -$0.80 |
| Q1 2026 | -$2.35 | -$1.11 |
| Q4 2025 | -$2.51 | -$1.51 |
| Q3 2025 | -$2.33 | -$1.40 |
| Q2 2025 | -$1.82 | -$0.90 |
| Q1 2025 | -$1.24 | -$0.35 |
| Q4 2024 | -$1.00 | -$0.24 |
QTRX lost $2.35 per share over the past year, about the same as its loss the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over QTRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over QTRX on profitability, with a higher operating margin.
QTRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35M | -13% |
| Q2 2026 | $32.9M | +34% |
| Q1 2026 | $36.4M | +20% |
| Q4 2025 | $43.9M | +25% |
| Q3 2025 | $40.2M | +12% |
| Q2 2025 | $24.5M | -29% |
| Q1 2025 | $30.3M | -5.4% |
| Q4 2024 | $35.2M | +11% |
QTRX's revenue is growing: $35M last quarter, down 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -64% | +29 points |
| Q2 2026 | -150% | +1.4 points |
| Q1 2026 | -114% | -27 points |
| Q4 2025 | -56% | -14 points |
| Q3 2025 | -93% | -60 points |
| Q2 2025 | -152% | -120 points |
| Q1 2025 | -87% | -40 points |
| Q4 2024 | -42% | +1.2 points |
QTRX's operating margin was −64% last quarter, up 28 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over QTRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
QTRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$16.3M | +$25.6M |
| Q2 2026 | -$5.2M | +$1.2M |
| Q1 2026 | -$18.2M | -$3.1M |
| Q4 2025 | -$16.3M | -$11.6M |
| Q3 2025 | -$41.9M | -$35.3M |
| Q2 2025 | -$6.4M | +$118K |
| Q1 2025 | -$15.1M | +$5.5M |
| Q4 2024 | -$4.7M | +$3.4M |
QTRX has burned cash in almost every quarter: −$56M over the past year, against −$68M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over QTRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
QTRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +221K shares |
| 1 year | +2.9% | +1.3M shares |
| 3 years | +26% | +9.7M shares |
| 5 years | +30% | +10.9M shares |
| Available history | +69% | +19.4M shares |
QTRX has 47M diluted shares, up 2.9% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
QTRX Net Leverage
QTRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
QTRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.1 | Neutral |
| Stochastic | 39.4 | Neutral |
QTRX's weekly RSI is 43 (neutral) and its Stochastic is 39 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
QTRX PE vs Healthcare Sector
QTRX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over QTRX on trend strength, trading above more of its moving averages.
QTRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.07 | 6.8% below |
| 20 week MA | $3.22 | 11% below |
| 50 week MA | $4.24 | 33% below |
| 100 week MA | $5.37 | 47% below |
| 200 week MA | $11.9 | 76% below |
QTRX is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over QTRX on returns for 2026, with the stronger performance.
QTRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.5 | $45.9 | +95% |
| 2021 | $45.9 | $43.9 | -4.5% |
| 2022 | $43.9 | $12.9 | -71% |
| 2023 | $12.9 | $27.3 | +112% |
| 2024 | $27.3 | $11.1 | -60% |
| 2025 | $11.1 | $6.46 | -42% |
| 2026 YTD | $6.46 | $2.86 | -56% |
QTRX's yearly returns have swung widely, from +112% in 2023 to −71% in 2022. It's down 56% so far in 2026.